twelv
aminoarylazocompound
ac
aryltriazen
deriv
dg
synthes
evalu
cellbas
assay
cytotox
antivir
activ
panel
rna
dna
virus
eight
aminoazocompound
aryltriazen
deriv
exhibit
antivir
activ
sometim
high
level
one
virus
mark
activ
bvdv
yfv
prevail
among
former
compound
latter
type
compound
affect
mainli
rsv
none
activ
compound
inhibit
multipl
vsv
vv
arrang
order
decreas
potenc
select
versu
host
cell
line
best
compound
follow
bvdv
yfv
rsv
compound
ec
rang
lm
lm
thu
aminoarylazo
aryltriazen
substructur
appear
interest
molecular
compon
develop
antivir
agent
ss
rna
virus
particularli
rsv
bvdv
import
human
veterinari
pathogen
final
molecular
model
investig
indic
compound
structur
ac
activ
bvdv
could
work
target
viral
rnadepend
rnapolymeras
rdrp
observ
good
agreement
trend
estim
ic
experiment
ec
valu
recent
shown
arylazoenamin
fig
endow
antivir
activ
vitro
rna
virus
particularli
rsv
bvdv
yfv
mani
case
ec
rang
lm
arylazoenamin
consid
substructur
ortho
para
aminoazocompound
mani
endow
antimicrobi
antiparasit
activ
addit
pharmacolog
activ
also
shown
particular
case
fig
pyridium
inhibit
variou
cocci
coli
bacilli
uracil
highli
effect
schistosoma
mansonii
amino
propylpiperidin
amino
lupinan
activ
mycobacterium
tuberculosi
antifung
antiprolif
activ
found
peculiar
class
cyclic
aminoazocompound
triazin
moreov
display
sever
pharmacolog
activ
depend
substitu
present
bicycl
system
potent
relax
activ
intestin
uterin
smooth
muscl
display
nanomolar
concentr
ndialkylaminoalkyl
deriv
anoth
cyclic
aminoazo
system
name
triazepin
exhibit
also
local
anesthet
antithrombot
activ
arylazoenamin
could
also
seen
vinylogu
aryltriazen
fig
class
compound
hold
import
posit
carcinogen
andor
anticanc
agent
even
better
dacarbazin
abl
methyl
dna
thu
former
result
power
carcinogen
latter
clinic
use
treatment
malign
melanoma
hodgkin
lymphoma
temozolamid
close
relat
dacarbazin
current
use
treat
malign
glyoma
recent
develop
cyclic
aryltriazen
repres
benzotriazepinon
promis
agent
breast
cancer
worth
note
compound
weak
alkyl
agent
may
damag
dna
novel
mechan
triazen
pharmacophor
link
bioactiv
moieti
order
obtain
chymer
compound
abl
exert
doubl
cytotox
mode
action
thu
triazen
group
link
backbon
known
inhibit
epiderm
growth
factor
receptor
tyrosin
kinas
egfrtk
also
benzophenon
residu
present
inhibitor
pharnesyltransferas
tubulinpolymer
introduct
triazen
group
molecul
pyrimethamin
dihydrofol
reductas
inhibitor
gener
compound
combin
antitumor
potenti
inhibit
pneumocysti
jirovecii
p
carinii
insert
triazen
group
two
benzamidin
unit
produc
diminazen
berenil
power
agent
african
trypanosomiasi
best
knowledg
antivir
activ
seen
either
amino
arylazocompound
aryltriazen
except
patent
claim
activ
tobacco
mosaic
viru
figur
biolog
activ
aminoarylazo
compound
aryltriazen
deriv
antivir
activ
shown
sever
benzotriazol
deriv
could
formal
consid
cyclic
triazen
though
reson
stabil
heterocycl
could
impli
even
substanti
differ
chemic
henc
biolog
behavior
two
kind
compound
interestingli
halogen
benzotriazol
shown
inhibit
ntpasehelicas
activ
hepat
c
relat
virus
aromat
heteroaromat
ester
found
strongli
inhibit
k
nm
essenti
replic
coronaviru
respons
sar
sever
acut
respiratori
syndrom
recent
set
benzotriazol
deriv
found
endow
potent
activ
rsv
moder
activ
yfv
bvdv
base
deem
interest
investig
possibl
antivir
activ
assort
aminoarylazo
compound
aryltriazen
deriv
allot
seven
group
ag
fig
whole
amino
arylazo
compound
ac
triazen
deriv
dg
evalu
cell
base
assay
cytotox
antivir
activ
larg
panel
rna
dna
virus
thirti
compound
evalu
antivir
activ
alreadi
known
prepar
accord
literatur
compound
alreadi
describ
us
report
known
r
fail
find
data
concern
character
refer
ar
concern
previous
describ
compound
avail
supplementari
data
novel
compound
prepar
accord
follow
scheme
new
compound
character
element
analys
h
nmr
spectra
n
n
lupinyl
requir
scheme
alreadi
describ
us
observ
presenc
group
prevent
complet
coupl
diazonium
salt
para
posit
nsubstitut
anilin
give
place
triazen
deriv
e
prepar
compound
amino
arylazocompound
ac
triazen
deriv
dg
evalu
vitro
parallel
cellbas
assay
cytotox
antivir
activ
tabl
virus
repres
two
three
genera
flavivirida
famili
flavivirus
yfv
pestivirus
bvdv
hepacivirus
hardli
use
routin
cellbas
assay
titl
compound
also
test
repres
viru
famili
among
ssrna
retroviru
human
immunodefici
viru
type
two
picornavirus
coxsacki
azt
azidothymidin
nm
cmethylguanosin
nm
cethynylcytidin
ribavirin
nm
mycophenol
acid
acg
acyclovir
use
refer
inhibitor
ssrna
dna
virus
respect
interestingli
aminoazocompound
triazen
deriv
test
compound
exhibit
antivir
activ
one
virus
particular
compound
exhibit
select
activ
singl
viru
respect
activ
two
three
four
virus
hand
compound
aminoarylazo
triazen
deriv
abl
inhibit
multipl
viru
concentr
lm
none
activ
compound
inhibit
multipl
vsv
vv
increas
number
exhibit
antivir
activ
order
bvdv
yfv
rsv
tabl
therefor
dialkylaminoalkyl
amino
azobenzen
aryltriazen
molecular
pattern
repres
interest
pharmacophor
develop
novel
antivir
agent
particularli
ssrna
virus
cytotox
antivir
activ
test
refer
compound
report
tabl
tabl
virus
activ
compound
found
indic
test
compound
show
differ
degre
cytotox
confluent
cell
monolay
stationari
growth
use
support
multipl
differ
virus
suscept
toxic
exponenti
grow
lymphoblastoid
human
cell
use
grow
nonhuman
host
cell
line
exhibit
progress
reduc
sensit
order
bhk
mdbk
hand
observ
toxic
evenli
distribut
among
differ
type
test
compound
mainli
shown
triazen
deriv
structur
e
amino
azo
compound
ac
character
presenc
basic
dimethylaminopropyl
lupinyl
moieti
inde
toxic
compound
mean
cc
valu
host
cell
lm
respect
group
triazen
deriv
structur
f
g
rel
non
toxic
exhibit
case
cc
p
lm
alreadi
seen
eight
dialkylaminoalkyl
amino
azobenzen
ac
triazen
deriv
dg
shown
antivir
activ
sometim
high
level
one
virus
tabl
appear
compound
structur
ac
mark
activ
bvdv
yfv
occasion
though
still
high
level
activ
rsv
whole
triazen
deriv
dg
character
frequent
activ
rsv
associ
decreas
frequenc
activ
yfv
bvdv
tabl
howev
consid
separ
subgroup
triazen
deriv
observ
activ
mainli
associ
pyrrolidinerel
triazen
f
activ
associ
diaryltriazen
bear
dimethylaminopropyl
chain
import
basic
chain
activ
underlin
high
activ
shown
compound
bear
dimethylaminopropyl
chain
even
link
aminoazobenzen
pharmacophor
also
moder
activ
triazen
contain
basic
nmethylpiperazin
residu
convers
worth
note
activ
bvdv
larg
diffus
among
amino
azo
compound
ac
rare
present
compound
among
triazen
deriv
dg
even
among
e
share
basic
chain
former
group
activ
inact
compound
found
side
side
group
ag
thu
molecular
pattern
seem
address
activ
differ
type
virus
substitu
aromat
nucleu
determin
activ
inact
howev
attempt
defin
gener
structureact
relationship
result
rather
frustrat
sinc
observ
hold
activ
virus
may
hold
other
inde
meta
substitut
halogen
trifluoromethyl
nitro
group
favor
display
activ
group
ae
g
compound
group
f
para
substitut
promot
activ
howev
occasion
except
observ
case
unsubstitut
aromat
ring
found
activ
inact
compound
presenc
electronreleas
group
ch
och
benzyl
residu
alway
detriment
express
activ
despit
high
antivir
activ
mani
compound
correspond
select
index
gener
low
due
rather
high
cytotox
exert
host
cell
compound
exhibit
higher
one
virus
compound
rang
remain
valu
take
account
ec
valu
best
compound
follow
arrang
order
decreas
potenc
select
bvdv
yfv
rsv
compound
ec
rang
lm
lm
correspond
valu
rang
though
activ
shown
compound
may
appear
particularli
impress
must
note
present
experiment
agent
known
act
virus
moreov
often
display
high
cytotox
particular
interest
deserv
compound
display
good
activ
rsv
bvdv
rsv
respons
seriou
respiratori
tract
infect
infant
elderli
immunocompromis
patient
high
mortal
rate
potent
antirsv
agent
interf
virushost
fusion
process
develop
last
year
benzimidazol
deriv
exhibit
ec
low
nm
howev
attempt
demonstr
therapeut
efficaci
success
probabl
due
rapid
emerg
resist
quit
recent
chiral
deriv
act
differ
mechan
though
much
less
potent
show
promis
characterist
examin
phase
ii
clinic
studi
nevertheless
chiralityassoci
develop
issu
underestim
sinc
antivir
activ
found
resid
mainli
senantiom
exhibit
ec
lm
racem
ic
lm
valu
compar
compound
hand
bvdv
prototyp
pestivirus
commonli
affect
clovenhoof
anim
cattl
swine
sheep
bvdv
infect
respons
reduc
dairi
product
increas
even
cattl
mortal
throughout
world
thu
avail
effect
inexpens
antipestiviru
drug
import
reliev
heavi
econom
burden
develop
antibvdv
drug
understand
mechan
action
interest
may
provid
valuabl
inform
design
agent
activ
hepat
c
viru
hcv
hcv
like
bvdv
belong
flavivirida
famili
infect
world
popul
sinc
chronic
hcv
infect
progress
fatal
cirrhosi
hepatocellular
carcinoma
develop
effect
safe
antihcv
agent
urgent
need
current
combin
therapi
pegyl
interferon
ribavirin
effect
less
treat
patient
associ
heavi
side
effect
understand
aspect
viru
replic
bvdv
consid
even
advantag
current
use
hcv
subgenom
replicon
system
last
year
sever
potent
antibvdv
agent
develop
shown
target
rnadepend
rnapolymeras
rdrp
even
result
almost
inact
purifi
enzym
compound
dipropylaminoethyl
thio
indol
bpip
exhibit
ec
low
nm
compound
thiazolylurea
tabl
cytotox
mdbk
bhk
cell
line
bvdv
yfv
rsv
inhibitori
activ
amino
azocompound
structur
ac
benzimidazolon
acridon
ec
rang
lm
compar
present
describ
aminoaryl
azocompound
lm
respect
structur
simplic
compound
allow
wide
rang
easi
inexpens
molecular
modif
make
attract
model
develop
activ
less
toxic
antipestiviru
agent
view
consider
deem
interest
perform
molecular
model
investig
studi
wether
bvdv
rdrp
could
target
also
compound
bvdv
beststudi
pestiviru
genom
consist
approxim
posit
sens
ssrna
bvdv
genom
translat
singl
polyprotein
process
least
four
structur
six
nonstructur
ns
protein
requir
viral
assembl
replic
among
nonstructur
protein
rnadepend
rnapolymeras
rdrp
enzym
respons
genom
replic
part
larger
membran
associ
replicas
complex
crystal
structur
rdrp
sever
famili
singleor
doublestrand
rna
virus
includ
hcv
bvdv
recent
made
avail
protein
data
bank
pdb
repositori
despit
low
sequenc
ident
differ
polymeras
crystal
structur
protein
bvdv
hcv
famili
ss
dsrna
virus
present
shape
right
hand
finger
palm
thumb
domain
particular
bvdv
rnadepend
rnapolymeras
core
domain
residu
dimens
approxim
around
central
caviti
serv
rna
templat
bind
nucleotid
recruit
polymer
reaction
see
fig
addit
ntermin
region
residu
residu
disord
relev
crystal
structur
thorough
search
put
bind
site
molecul
onto
bvdv
rdrp
conduct
follow
success
recip
develop
studi
alloster
inhibitor
polioviru
helicas
portion
enzym
make
bind
site
interact
inhibitor
locat
finger
domain
residu
consist
ahelic
bstrand
see
fig
bvdv
rdrp
viral
rdrp
n
terminu
finger
domain
togeth
long
insert
finger
domain
residu
form
fingertip
region
associ
thumb
domain
region
character
threestrand
conform
sinc
finger
thumb
domain
associ
fingertip
region
conform
chang
induc
rna
templat
bind
central
channel
somewhat
limit
remaind
finger
domain
compris
bstrand
rich
region
bfinger
ahelix
rich
region
afing
close
palm
domain
accord
procedur
adopt
compound
character
similar
dock
mode
put
bind
site
bvdv
rdrp
exemplifi
compound
figur
particular
residu
line
pocket
see
fig
includ
side
chain
residu
belong
loop
two
strand
residu
loop
strand
amino
acid
contribut
bind
bsheet
portion
whilst
anoth
loop
connect
two
ahel
motif
respect
concur
residu
go
detail
aminoalkyl
part
molecul
engag
stabil
nonbond
interact
apolar
side
chain
residu
diarylazo
moieti
nice
encas
subsit
line
side
chain
importantli
howev
molecular
scaffold
anchor
place
three
persist
hydrogen
bond
hb
first
hb
bridg
involv
nitrogen
atom
n
ch
substitu
group
oh
group
side
chain
averag
dynam
length
adl
second
hb
interact
engag
termin
amino
group
n
atom
inhibitor
secondari
amino
group
adl
final
one
nitrogen
atom
belong
azo
group
character
compound
involv
third
hb
interact
backbon
nh
group
adl
importantli
quantit
inform
affin
ligand
toward
bvdv
rdrp
infer
appli
mm
pbsa
methodolog
estim
free
energi
bind
dg
bind
compon
calcul
dg
bind
valu
dimethylaminopropyl
deriv
quinolizidinylmethyl
deriv
list
tabl
gener
speak
harmoni
previou
find
nonbond
mechan
energi
compon
dg
bind
de
vdw
de
el
afford
substanti
favor
contribut
bind
seri
compound
hand
due
polar
charact
azo
group
desolv
penalti
paid
molecul
upon
bind
dg
pb
also
quit
substanti
net
result
electrostat
contribut
affin
inhibitor
enzym
receptor
notabl
unfavor
specif
seri
compound
mean
valu
electrostat
energi
de
el
dg
pb
kcalmol
whilst
correspond
mean
valu
van
der
waal
hydrophob
overal
interact
energi
de
vdw
dg
np
kcalmol
accordingli
follow
associ
ligand
rdrp
mainli
driven
favor
nonpolar
interact
complex
solut
harmoni
propos
gener
scheme
noncoval
associ
howev
indic
instanc
energi
compon
compound
drive
forc
weaken
polar
group
molecul
find
adequ
bond
pattern
protein
compar
water
free
energi
penalti
de
el
dg
pb
term
least
compound
togeth
substanti
van
der
waal
contribut
moder
entrop
unfavor
term
consequ
lead
one
highest
bind
affin
set
inhibitor
one
import
benchmark
studi
howev
correspond
estim
free
energi
bind
experiment
measur
ec
valu
inde
observ
good
agreement
trend
exhibit
ic
valu
report
tabl
correspond
biolog
activ
determin
compound
bvdv
infect
cell
line
see
tabl
although
obvious
directli
compar
comput
bind
free
energi
henc
correspond
ic
ec
valu
deriv
experi
observ
case
rank
inhibitor
respect
activ
toward
put
target
rdrp
bvdv
maintain
although
discrep
fact
estim
ic
valu
systemat
higher
determin
vitro
experi
infect
cell
line
overal
result
obtain
molecular
model
deserv
comment
first
bind
site
identifi
procedur
close
put
bind
site
propos
two
alloster
inhibitor
bvdv
rdrp
bpip
tabl
cytotox
mdbk
bhk
cell
line
yfv
rsv
inhibitori
activ
triazen
deriv
structur
f
g
tabl
involv
residu
see
fig
residu
found
mutat
bvdv
bpipresist
clone
bind
pocket
locat
turn
finger
domain
two
bsheet
believ
involv
finger
flexibl
rna
templateproduct
transloc
dimer
rdrp
replic
complex
proteinprotein
interact
enabl
assembl
activ
replic
complex
accord
dock
result
hypothet
bind
compound
polymeras
could
affect
finger
flexibl
impair
capac
protein
transloc
templateproduct
rna
polymer
altern
diarylazo
moieti
could
possibl
act
hamper
entranc
templat
rna
templat
bind
caviti
although
silico
data
clearli
show
trend
correspond
experiment
ec
valu
time
yield
evid
bind
inhibitor
onto
bvdv
rdrp
result
real
alloster
inhibit
enzym
reduc
templatebind
abil
one
explan
find
ic
valu
higher
correspond
ec
could
explain
follow
rational
recent
attempt
cocrystal
bvdv
rdrp
inhibitor
fail
dimer
interfac
near
put
bind
site
bvdv
rdrp
crystal
author
work
propos
format
dimer
could
constitut
import
point
replic
complex
moreov
also
hypothes
top
finger
domain
could
proteindock
site
pivot
interact
enzym
replicas
complex
bind
site
part
put
bind
pocket
molecular
seri
could
upon
bind
compound
hinder
interact
among
differ
protein
make
replicas
complex
last
least
import
recal
rdrp
function
virusinfect
cell
context
membranebound
replic
complex
usual
consist
sever
virusencod
protein
host
protein
variou
form
viral
rna
rnadepend
rna
polymeras
may
role
interact
compon
andor
stabil
replic
complex
one
put
action
rdrp
infect
cell
sensit
inhibitor
viral
rna
synthesi
may
disrupt
manner
distinct
one
estim
silico
assay
given
similar
among
polymeras
pestivirus
hepacivirus
flavivirus
knowledg
gain
one
viral
system
like
foster
progress
other
given
high
import
hepat
c
pandem
stringent
need
effici
therapeut
patholog
expect
new
molecular
entiti
describ
work
provid
meaning
insight
toward
identif
possibl
antihcv
agent
interestingli
overal
sequenc
ident
bvdv
hcv
rdrp
protein
quit
low
approxim
consid
align
bvdv
hcv
rdrp
report
figur
particular
focu
highlight
finger
domain
part
immedi
specul
residu
bvdv
protein
counterpart
correspond
hcv
enzym
accordingli
drug
would
bind
bind
pocket
bind
mode
principl
problem
resist
mutant
posit
ii
import
region
bvdv
rdrp
highli
conserv
correspond
hcv
polymeras
knek
bvdv
knev
hcv
respect
see
fig
importantli
engag
fundament
stabil
hydrogen
bond
inhibitor
bvdv
case
conserv
abl
establish
interact
compound
also
case
hcv
iii
residu
bvdv
rdrp
conserv
correspond
hcv
polymeras
replac
phenylalanin
therefor
anchor
hydrogen
bond
oh
group
instanc
tertiari
nitrogen
longer
take
place
taken
togeth
evid
justifi
minor
potenc
molecular
seri
toward
hcv
rdrp
target
respect
bvdv
counterpart
time
case
virus
bind
pocket
respect
rdrp
share
suffici
degre
structur
sequenc
homolog
thu
sinc
region
involv
finger
domain
overhang
palm
domain
enzym
might
involv
rna
substrat
recognit
henc
side
chain
residu
form
primari
bind
pocket
interact
compound
shown
stick
model
atom
colorcod
follow
firebrick
orang
dark
kaki
red
dim
gray
rosi
brown
green
hot
pink
tan
sienna
dark
magenta
gold
navi
blue
purpl
dark
slate
blue
pink
oliv
drab
coral
kaki
hydrogen
bond
highlight
light
gray
broken
line
hydrogen
atom
counterion
water
molecul
omit
clariti
free
energi
compon
total
bind
free
energi
compound
seri
ac
bvdv
rdrp
inhibitor
molecul
may
affect
rdrp
interact
incom
rna
molecul
twelv
aminoarylazocompound
structur
ac
aryltriazen
deriv
dg
synthes
assay
antivir
activ
panel
rna
dna
virus
thirtyf
aminoazocompound
triazen
deriv
test
compound
exhibit
antivir
activ
one
virus
mani
shown
ec
lm
least
one
viru
none
activ
compound
inhibit
multipl
vsv
vv
aminoazocompound
ac
mark
activ
bvdv
yfv
triazen
deriv
dg
character
frequent
activ
rsv
despit
high
antivir
activ
mani
compound
correspond
select
index
gener
low
due
rather
high
cytotox
exert
host
cell
line
take
account
ec
particular
interest
deserv
compound
display
good
activ
rsv
bvdv
former
viru
respons
seriou
respiratori
tract
infect
human
high
mortal
rate
latter
respons
sever
epidem
outbreak
livestock
also
surrog
model
evalu
novel
urgent
need
agent
hcv
emerg
threat
human
health
worldwid
compound
repres
valuabl
start
model
develop
better
potent
less
toxic
inexpens
antivir
agent
variat
dialkylaminoalkyl
chain
andor
substitu
aromat
ring
view
consider
molecular
model
investig
perform
studi
wether
activ
compound
structur
ac
could
target
bvdv
rnadepend
rnapolymeras
rdrp
share
structur
similar
hcv
rdrp
inde
good
agreement
observ
trend
exhibit
ic
calcul
estim
free
energi
bind
correspond
biolog
activ
determin
compound
bvdv
infect
mdbk
cell
line
overal
sequenc
ident
bvdv
hcv
rdrp
protein
approxim
import
region
bvdv
rdrp
highli
conserv
correspond
hcv
polymeras
thu
target
hcv
rdrp
ac
molecular
seri
could
expect
even
minor
potenc
respect
bvdv
counterpart
solut
arylamin
mmol
ml
conc
hydrochloridr
acid
ml
water
cool
slowli
diazot
solut
sodium
nitrit
mmol
ml
water
diazonium
salt
solut
ad
dropwis
min
cold
water
solut
n
anilin
monoacet
mmol
maintain
care
ph
simultan
addit
satur
solut
sodium
acet
stir
reaction
mixtur
min
oil
product
extract
et
dri
vacuumdistil
torr
remov
unreact
nsubstitut
anilin
residu
fraction
cc
elut
firstli
et
triazen
deriv
e
et
meoh
isomer
azocompound
quit
lower
yield
isol
compound
purifi
either
crystal
oili
second
cc
distil
aromat
amin
mmol
dissolv
ml
conc
hydrochloridr
acid
ml
water
cool
ice
bath
solut
kept
ad
drop
drop
solut
sodium
nitrit
mmol
ml
water
diazonium
salt
coupl
relev
amin
mmol
dissolv
ml
n
naoh
ph
min
stir
precipit
collect
filtrat
solid
crystal
suitabl
solvent
case
compound
proper
oili
anilin
ad
diazonium
salt
solut
follow
solut
sodium
acet
reduc
acid
couplingproduct
separ
oil
compound
extract
et
remov
solvent
oil
purifi
cc
cytisin
deriv
extract
chcl
solid
obtain
crystal
aceton
cell
line
purchas
american
type
cultur
collect
atcc
absenc
mycoplasma
contamin
check
period
hoechst
stain
method
cell
line
support
multipl
rna
dna
virus
follow
human
tcell
contain
integr
genom
madin
darbi
bovin
kidney
mdbk
babi
hamster
kidney
monkey
kidney
vero
cell
cytotox
test
run
parallel
antivir
assay
mdbk
bhk
cell
resuspend
multiwel
plate
initi
densiti
cellsml
respect
mainten
medium
without
serial
dilut
test
compound
cell
viabil
determin
h
humidifi
co
atmospher
bromid
mtt
method
vero
cell
resuspend
multiwel
plate
initi
densiti
cellsml
cell
number
vero
monolay
determin
stain
crystal
violet
dye
cytotox
evalu
exponenti
grow
cell
deriv
human
hematolog
tumor
human
tcell
contain
integr
genom
seed
initi
densiti
cellsml
well
plate
medium
supplement
fetal
calf
serum
fc
unitsml
penicillin
g
lgml
streptomycin
cell
cultur
incub
humidifi
co
atmospher
absenc
presenc
serial
dilut
test
compound
cell
viabil
determin
h
mtt
method
activ
compound
human
immunodefici
activ
compound
yellow
fever
viru
yfv
reo
viru
base
inhibit
virusinduc
cytopathogen
acut
infect
cell
activ
bovin
viral
diarrhoea
viru
bvdv
infect
mdbk
cell
also
base
inhibit
virusinduc
cytopathogen
bhk
mdbk
cell
seed
plate
densiti
cellswel
respect
allow
form
confluent
monolay
incub
overnight
growth
medium
humidifi
co
atmospher
cell
monolay
infect
proper
viru
dilut
serumfre
medium
give
moi
one
hour
later
mem
earl
medium
supplement
inactiv
fetal
calf
serum
fc
final
concentr
without
serial
dilut
test
compound
ad
day
incub
cell
viabil
determin
mtt
method
activ
compound
coxsacki
viru
type
polio
viru
sabin
strain
vesicular
stomat
viru
vsv
vaccinia
viru
vv
herp
viru
respiratori
syncyti
viru
rsv
strain
infect
vero
cell
determin
plaqu
reduct
assay
vero
cell
monolay
end
vero
cell
seed
plate
densiti
cellswel
allow
form
confluent
monolay
incub
overnight
growth
medium
humidifi
co
atmospher
monolay
infect
proper
viru
dilut
give
pfuwel
follow
remov
unadsorb
viru
dulbecco
modifi
eagl
medium
supplement
inactiv
fc
methylcellulos
without
serial
dilut
test
compound
ad
cultur
incub
vsv
vv
day
rsv
fix
pb
contain
ethanol
crystal
violet
wash
airdri
plaqu
count
ec
effect
concentr
calcul
linear
regress
techniqu
et
al
coupl
algorithm
separ
coupl
solut
solvent
heat
integr
time
step
fs
applic
shake
algorithm
constrain
bond
equilibrium
valu
thu
remov
high
frequenc
vibrat
longrang
nonbond
van
der
waal
interact
truncat
use
dual
cutoff
respect
energi
forc
due
interact
updat
everi
time
step
particl
mesh
ewald
method
use
treat
longrang
electrostat
calcul
bind
free
energi
rdrp
inhibitor
water
total
snapshot
save
md
data
collect
period
describ
one
snapshot
per
ns
md
simul
bind
free
energi
dg
bind
rdrpdrug
complex
water
calcul
accord
procedur
term
molecular
mechanicpoissonboltzmann
surfac
area
mmpbsa
origin
propos
srinivasan
et
al
mmpbsa
framework
theori
bind
free
energi
given
ligand
receptor
protein
evalu
individu
term
mmpbsa
approach
contribut
free
energi
molecul
e
mm
denot
sum
intraand
intermolecular
mechan
mm
energi
molecul
ga
phase
g
solv
solvat
free
energi
ts
solut
repres
estim
solut
entropi
e
mm
divid
term
aris
electrostat
e
el
van
der
waal
e
vdw
intern
e
int
ie
bond
angl
torsion
energi
solvat
free
energi
consist
polar
solvat
energi
compon
g
pb
calcul
continuum
solvent
usual
finitediffer
poissonboltzmann
pb
model
nonpolar
term
g
np
proport
solventaccess
surfac
area
sa
ensembl
structur
uncomplex
reactant
gener
either
run
separ
md
simul
use
trajectori
complex
simpli
remov
atom
protein
ligand
work
appli
latter
variant
accordingli
term
e
int
eq
cancel
calcul
free
energi
bind
calcul
polar
solvat
term
g
pb
done
delphi
packag
interior
exterior
dielectr
constant
equal
respect
grid
space
extend
beyond
dimens
solut
employ
nonpolar
compon
g
np
obtain
use
follow
relationship
g
np
csa
b
c
kcal
mol
b
kcalmol
surfac
area
estim
mean
msm
softwar
last
paramet
eq
chang
solut
entropi
upon
associ
ts
solut
calcul
normalmod
analysi
first
step
calcul
sphere
around
ligand
cut
md
snapshot
ligandprotein
complex
valu
shown
larg
enough
yield
converg
mean
chang
solut
entropi
basi
sizereduc
snapshot
complex
gener
structur
uncomplex
reactant
remov
atom
protein
ligand
respect
structur
minim
use
distancedepend
dielectr
constant
e
account
solvent
screen
entropi
calcul
use
classic
statist
formula
normal
modeanalysi
minim
effect
due
differ
conform
adopt
individu
snapshot
averag
estim
entropi
snapshot
